Purchase this article with an account.
L. Rung, II, M. Lövestam-Adrian, II; Near Vision Improved and the Patients Well-Being Increased After Treatment With Ranibizumab for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2010;51(13):975.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the visual outcome and self-reported vision-targeted health status for persons treated with ranibizumab for wet ,age-related macular degeneration (AMD).
66 eyes from 66 patients (aged 76+-7 years) not previously treated and with wet AMD were included in the study.The mean self-reported duration of the disease before treatment was 14+-10 weeks.Best corrected visual acuity(VA) was examined using Early Treatment Diabetic Research Study (ETDRS) charts and near vision reading.All patients underwent an ophthalmological examination including fluorescein and indocyanine green angiography and optical coherence tomography (OCT).The visual Function Questionnaire(VFQ-25) test was answered before and 3 months after the intravitreal injections.
Mean VA increased from 53+-7 to 59+-13 letters (p=0.001), and near vision improved from 17+-9 to 12+-8 points (p=0.001).Neither age nor duration of the disease showed any correlation to visual improvement The life qulity test revealed an improvement in mental health (less worrying) from 46+-27 to 56+-27 points(p=0.002), and better control over what I am doing from 49+-40 to 60+-38 points (p=0.01)In addition near vision related items(reading newspaper) increased from 40+-29 to 52+-33 points(p=0.001), and to find things on a crowded shelf from 58+-27 to 64+-28 points(p=0.043).There was also a correlation between higher scores for color vision and general vision in the VFQ-25 test and improvement in VA at follow-up:Spearmans's rho r = +0.28; p =0,023 and r =+0.29; p =0,016 resp
Both near vision and VFQ-25 life qulity related items improved after treatment with ranibizumab for age related macular degeneration.
This PDF is available to Subscribers Only